Related Experiment Video
Updated: Jan 15, 2026

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes
Published on: January 12, 2024
A double-edged sword of neo-substrate degradation in PROTACs
Zihan Song1, Chengze Duan1, Mingfei Wu1
1School of Pharmaceutical Sciences, Hangzhou Medical College, Hangzhou, Zhejiang, China.
None:
Immunomodulatory drugs (IMiDs), including thalidomide and its derivatives, serve as widely used E3 ligase ligand for cereblon (CRBN) recruitment in proteolysis targeting chimeras (PROTACs) development. CRBN-based PROTACs may independently induce neo-substrate degradation while mediating target protein degradation. The synergistic effects of IMiD-PROTACs present innovative therapeutic strategy for disease treatment. However, conversely, such off-target degradation potentially contributing to several toxic liabilities. This perspective systematically reviews current advances in harnessing synergistic effects and mitigating neo-substrates degradation in CRBN-based PROTACs research and development. Additionally, we comprehensively discuss medicinal chemistry strategies to eliminate off-target effects associated with neo-substrate degradation in CRBN-based PROTAC systems. This work provides guidance for optimizing CRBN-based PROTACs through rational modulation of neo-substrates degradation, enabling either elimination or preservation of these effects as therapeutically required.
More Related Videos
05:33High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
Published on: November 9, 2020
07:49Spontaneous Formation and Rearrangement of Artificial Lipid Nanotube Networks as a Bottom-Up Model for Endoplasmic Reticulum
Published on: January 22, 2019
Related Concept Videos
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
ATP Synthase: Mechanism